Get the Stockscreener App
1.20
1.69%
0.02
After Hours:
1.17
-0.03
-2.50%
Icecure Medical Ltd stock is traded at $1.20, with a volume of 170.34K.
It is up +1.69% in the last 24 hours and up +1.69% over the past month.
Icecure Medical Ltd is a commercial-stage medical device company. The company is engaged in the research, development, and marketing of cryoablation systems and technologies based on liquid nitrogen, or LN2, for treating tumors. Its cryoablation technology is a minimally invasive alternative to surgical intervention, for tumors, including those found in the breast, lungs, kidneys, bones, and other indications.
See More
Previous Close:
$1.18
Open:
$1.202
24h Volume:
170.34K
Relative Volume:
0.58
Market Cap:
$63.89M
Revenue:
$3.67M
Net Income/Loss:
$-13.83M
P/E Ratio:
-4.2857
EPS:
-0.28
Net Cash Flow:
$-10.79M
1W Performance:
+6.67%
1M Performance:
+1.69%
6M Performance:
+93.55%
1Y Performance:
+0.84%
1-Day Range:
$1.17
$1.2252
1-Week Range:
$1.09
$1.2252
52-Week Range:
$0.48
$1.66
Icecure Medical Ltd Stock (ICCM) Company Profile
Compare ICCM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ICCM
Icecure Medical Ltd
|
1.20 | 63.89M | 3.67M | -13.83M | -10.79M | -0.28 |
|
ABT
Abbott Laboratories
|
128.85 | 225.27B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
101.90 | 138.41B | 17.55B | 2.03B | 2.37B | 1.37 |
|
SYK
Stryker Corp
|
365.06 | 129.62B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
84.16 | 107.92B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
76.04 | 40.53B | 5.54B | 4.18B | 259.90M | 7.00 |
Icecure Medical Ltd Stock (ICCM) Latest News
IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogenic Pump for its Next-Generation Cryoablation Systems - marketscreener.com
IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation - StreetInsider
IceCure's ProSense® Featured at European Conference on Interventional Oncology with an Emphasis on Breast Cancer Cryoablation | ICCM Stock News - GuruFocus
Clinical Trial Reveals Revolutionary Breast Cancer Treatment: ProSense Shows 94% Success, Zero Complications - Stock Titan
IceCure Medical (NASDAQ:ICCM) Shares Down 3.1% – Time to Sell? - Defense World
IceCure Medical Announces Special Shareholder Meeting for May 2025 - TipRanks
FY2027 EPS Estimates for IceCure Medical Reduced by Analyst - Defense World
IceCure Medical (NASDAQ:ICCM) Earns Buy Rating from HC Wainwright - Defense World
IceCure Medical Stock Dips Despite Positive ICESECRET Study Results - Zacks Investment Research
Genomic Differences Impact Real World Use of Elacestrant in Breast Cancer - Targeted Oncology
H.C. Wainwright maintains Buy on IceCure Medical with $2.50 target By Investing.com - Investing.com India
IceCure Medical Ltd (NASDAQ:ICCM) Q4 2024 Earnings Call Transcript - Insider Monkey
H.C. Wainwright maintains Buy on IceCure Medical with $2.50 target - Investing.com
IceCure Medical Reports Growth and Awaits FDA Decision - TipRanks
IceCure Medical Ltd’s Earnings Call: Growth Amidst Challenges - TipRanks
IceCure Medical to Report 2024 Full Year Financial & Operational Results on March 27, 2025 - PR Newswire
Earnings call transcript: Icecure Medical’s Q4 2024 sees growth in sales but wider losses By Investing.com - Investing.com South Africa
Earnings call transcript: Icecure Medical’s Q4 2024 sees growth in sales but wider losses - Investing.com
IceCure Medical Reports 2024 Financial Results: 42% Growth in ProSense® Cryoablation Sales in North America - StreetInsider.com
Earnings Outlook For Icecure Medical - Benzinga
IceCure Medical aims to bring cold cancer treatment to Vietnam - Mugglehead Magazine
IceCure Medical (ICCM) Projected to Post Earnings on Thursday - Defense World
IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Results Presented at European Association of Urology Conference in Spain: 88.7% Recurrence-Free Rate - The Malaysian Reserve
IceCure's ICESECRET Kidney Cancer Cryoablation Study Interim Res - GuruFocus
IceCure reports high efficacy in kidney tumor cryoablation study By Investing.com - Investing.com South Africa
IceCure reports high efficacy in kidney tumor cryoablation study - Investing.com India
IceCure Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense® Cryoablation in Early-Stage Breast Cancer - The Malaysian Reserve
Targeting ESR1 Mutations in Breast Cancer With Novel Therapies - Targeted Oncology
IceCure stock tumbles after update on ProSense (ICCM:NASDAQ) - Seeking Alpha
IceCure Medical Ltd. Reports Updated Timeline and Progress with FDA Regarding Marketing Authorization for ProSense®? Cryoablation in Early-Stage Breast Cancer - Marketscreener.com
IceCure Medical Expects FDA Decision on ProSense After Q1 -March 20, 2025 at 09:20 am EDT - Marketscreener.com
IceCure nears FDA decision on breast cancer treatment - Investing.com
IceCure nears FDA decision on breast cancer treatment By Investing.com - Investing.com UK
IceCure's ProSense® Cryoablation Featured in Six Studies Presented at St. Gallen International Breast Cancer Conference - PR Newswire
Critical Survey: IceCure Medical (NASDAQ:ICCM) and Medifocus (OTCMKTS:MDFZF) - Defense World
IceCure secures patent for cryogenic pump in China By Investing.com - Investing.com Australia
IceCure Receives Notice of Allowance in China for Novel Cryogenic Pump for Next-Generation Cryoablation Technology - Quantisnow
IceCure Gets Notice of Allowance from China's Intellectual Property Regulator -March 17, 2025 at 09:07 am EDT - MarketScreener
IceCure secures patent for cryogenic pump in China - Investing.com
Market Sentiment Around Loss-Making IceCure Medical Ltd (NASDAQ:ICCM) - Simply Wall St
IceCure's ProSense® Cryoablation Featured in Six Studies Present - GuruFocus.com
Breast Cancer Patients Report Higher Satisfaction with Cryoablation - Imaging Technology News
Icecure Medical Ltd Stock (ICCM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.01%
0.60%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):